logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals receives ethics approval as they begin clinical trials for Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling to announce the company has received ethics approval from a central institutional review board for U.S. study sites for its multinational Phase 2b/3 human study of Ifenprodil for COVID-19.

Moreau explains what that means going forward and he also updated the situation in South Korea and the good news from that country when it comes to the coronavirus.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.255 CAD

CSE:AGN
Market: CSE
Market Cap: $22.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tabula launches new ETF focussing on North American High Yield Credit Market

Tabula Investment Management Limited (LSE: TABS) CEO MJ Lytle joined Steve Darling from Proactive with news the company has started a new ETF that will be exclusively located on the London Stock Exchange under the ticker “TABS”  Lytle telling Proactive that ETF will focus on short exposure...

12 hours, 4 minutes ago

2 min read